(1R,3S)-3-[4-{5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl}phenylamino]cyclopentanecarboxylic acid | 1311231-63-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,3S)-3-[4-{5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl}phenylamino]cyclopentanecarboxylic acid
• 英文别名: (1R,3S)-3-(4-(5-(5-Chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)phenylamino)cyclopentanecarboxylic acid；(1R,3S)-3-[4-[5-(5-chloro-6-propan-2-yloxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]anilino]cyclopentane-1-carboxylic acid
• CAS: 1311231-63-6
• 化学式: C₂₂H₂₃ClN₄O₄
• 分子量: 442.902
• InChiKey: KXQNATKLRZLEJT-PBHICJAKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (1R,3S)-3-[4-{5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl}phenylamino]cyclopentanecarboxylic acid 在 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 120.0h， 生成 (1R,3S)-3-(4-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)phenylamino)cyclopentanecarboxylic acid potassium salt
  参考文献：
  名称：

  [1,2,4]OXADIAZOL-3-YL ACID SALTS AND CRYSTALLINE FORMS AND THEIR PREPARATION

  摘要：

  本发明涉及[1,2,4]噁二唑-3-基]-苯氧基}-环烷基羧酸的盐和结晶形式，其制备方法，包含这些化合物的药物组合物，以及使用它们的方法。

  公开号：

  US20120214848A1
• 作为产物：
  描述：

  ethyl (1R,3S)-3-[4-{5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl}phenylamino]cyclopentanecarboxylate 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 叔丁醇 、 乙醇 、 水 为溶剂， 反应 1.0h， 以90%的产率得到(1R,3S)-3-[4-{5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl}phenylamino]cyclopentanecarboxylic acid
  参考文献：
  名称：

  PROCESS FOR THE PREPARATION OF 1,2,4-OXADIAZOL-3-YL DERIVATIVES OF CARBOXYLIC ACID

  摘要：

  本发明公开了制备和分离羧酸的[1,2,4]氧二唑-3-基衍生物的方法。这些衍生物在治疗炎症性疾病和症状中具有用途。

  公开号：

  US20120232277A1

文献信息

• PROCESS FOR THE PREPARATION OF 1,2,4-OXADIAZOL-3-YL DERIVATIVES OF CARBOXYLIC ACID
  申请人：Lukin Kirill A.

  公开号：US20120232277A1

  公开（公告）日：2012-09-13

  The present invention discloses processes for the preparation and isolation of [1,2,4]oxadiazo-3-yl derivatives of carboxylic acids. The derivatives are useful in the treatment of inflammatory diseases and conditions.

  本发明公开了制备和分离羧酸的[1,2,4]氧二唑-3-基衍生物的方法。这些衍生物在治疗炎症性疾病和症状中具有用途。
• Novel Oxadiazole Compounds
  申请人：Cusack Kevin P.

  公开号：US20110207704A1

  公开（公告）日：2011-08-25

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  本发明涉及新型噁二唑类化合物、含有该类化合物的制药组合物，以及将这些化合物或组合物作为S1P家族G蛋白偶联受体的激动剂或拮抗剂，用于治疗与S1P家族受体活性调节相关的疾病，特别是通过提供有益的免疫抑制作用。
• [EN] PROCESS FOR THE PREPARATION OF 1,2,4-OXADIAZOL-3-YL DERIVATIVES OF CARBOXYLIC ACID<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS 1,2,4-OXADIAZOL-3-YLE D'ACIDE CARBOXYLIQUE
  申请人：ABBOTT LAB

  公开号：WO2012122338A1

  公开（公告）日：2012-09-13

  The present invention discloses processes for the preparation and isolation of [l,2,4]oxadiazo-3-yl derivatives of carboxylic acids. The derivativehe present invention discloses are useful in the treatment of inflammatory diseases and conditions.
• [1,2,4]OXADIAZOL-3-YL ACID SALTS AND CRYSTALLINE FORMS AND THEIR PREPARATION
  申请人：Zhang Geoff G.

  公开号：US20120214848A1

  公开（公告）日：2012-08-23

  The present invention relates to salts and crystalline forms of [1,2,4]oxadiazol-3-yl]-phenoxy}-cycloalkyl carboxylic acids, processes for their preparation, pharmaceutical compositions comprising such compounds, and methods of using them.

  本发明涉及[1,2,4]噁二唑-3-基]-苯氧基}-环烷基羧酸的盐和结晶形式，其制备方法，包含这些化合物的药物组合物，以及使用它们的方法。
• Development of a Scalable Synthesis of Oxadiazole Based S1P₁ Receptor Agonists
  作者：Kirill Lukin、Vimal Kishore、Thomas Gordon

  DOI：10.1021/op300345v

  日期：2013.4.19

  A robust and scalable synthesis was developed for the preparation of oxadiazole based SIP, inhibitors. A new method for the separation of triphenylphosphine oxide from reaction products and an improved method for the synthesis of oxadiazoles in the presence of DBU were incorporated into the process to achieve its scalability.